Stakeholders Urge Major Changes To PBS Listing Guidelines
This article was originally published in Scrip
The future shape of Australia's system for listing medicines on the Pharmaceutical Benefits Scheme (PBS) is becoming clearer after the government published stakeholder responses to a consultation on the long-awaited review of the Pharmaceutical Benefits Advisory Committee (PBAC) guidelines, which are used by the pharmaceutical industry to prepare requests for PBS listing.
You may also be interested in...
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.